• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study.

作者信息

Gómez-Randulfe Igor, Califano Raffaele

机构信息

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

Division of Cancer Sciences, The University of Manchester, Manchester, UK.

出版信息

Transl Lung Cancer Res. 2023 Aug 30;12(8):1812-1815. doi: 10.21037/tlcr-23-290. Epub 2023 Aug 15.

DOI:10.21037/tlcr-23-290
PMID:37691870
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10483088/
Abstract
摘要

相似文献

1
Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study.基于成功：KEYNOTE-407研究5年更新的关键要点
Transl Lung Cancer Res. 2023 Aug 30;12(8):1812-1815. doi: 10.21037/tlcr-23-290. Epub 2023 Aug 15.
2
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.帕博利珠单抗单药治疗 PD-L1 阳性晚期非小细胞肺癌老年患者的安全性和有效性：来自 KEYNOTE-010、KEYNOTE-024 和 KEYNOTE-042 研究的汇总分析。
Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.
3
Overall Survival With Second-Line Pembrolizumab in Patients With Non-Small-Cell Lung Cancer: Randomized Phase III Clinical Trial Versus Propensity-Adjusted Real-World Data.二线帕博利珠单抗治疗非小细胞肺癌患者的总生存：随机 III 期临床试验与倾向评分调整的真实世界数据比较。
JCO Clin Cancer Inform. 2021 Jan;5:56-65. doi: 10.1200/CCI.20.00099.
4
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.帕博利珠单抗联合化疗治疗鳞状非小细胞肺癌：III 期 KEYNOTE-407 研究的 5 年更新结果。
J Clin Oncol. 2023 Apr 10;41(11):1999-2006. doi: 10.1200/JCO.22.01990. Epub 2023 Feb 3.
5
Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042.帕博利珠单抗单药治疗程序性死亡配体1阳性且伴有脑转移的非小细胞肺癌患者的疗效：KEYNOTE-001、010、024和042的汇总分析
JTO Clin Res Rep. 2021 Jul 1;2(8):100205. doi: 10.1016/j.jtocrr.2021.100205. eCollection 2021 Aug.
6
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.帕博利珠单抗对比化疗用于未经治疗的、PD-L1 阳性的局部晚期或转移性非小细胞肺癌中国患者的随机临床研究：KEYNOTE-042 中国研究。
Int J Cancer. 2021 May 1;148(9):2313-2320. doi: 10.1002/ijc.33399. Epub 2020 Dec 9.
7
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.KEYNOTE-010 研究：帕博利珠单抗对比多西他赛用于治疗既往接受过治疗、PD-L1 阳性的晚期 NSCLC 的 5 年生存更新。
J Thorac Oncol. 2021 Oct;16(10):1718-1732. doi: 10.1016/j.jtho.2021.05.001. Epub 2021 May 26.
8
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.帕博利珠单抗联合铂类化疗治疗 NSCLC 合并稳定脑转移患者的疗效：KEYNOTE-021、-189 和 -407 的汇总分析。
J Thorac Oncol. 2021 Nov;16(11):1883-1892. doi: 10.1016/j.jtho.2021.06.020. Epub 2021 Jul 12.
9
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.帕博利珠单抗联合化疗对比单纯化疗用于无肿瘤 PD-L1 表达的晚期非小细胞肺癌患者：3 项随机对照研究的汇总分析。
Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11.
10
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.既往放疗与帕博利珠单抗治疗非小细胞肺癌的临床活性及毒性：KEYNOTE-001 1期试验的二次分析
Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24.

引用本文的文献

1
Persistent lineage plasticity driving lung cancer development and progression.持续的谱系可塑性驱动肺癌的发生和发展。
Clin Transl Med. 2025 Aug;15(8):e70458. doi: 10.1002/ctm2.70458.

本文引用的文献

1
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.帕博利珠单抗联合化疗治疗鳞状非小细胞肺癌：III 期 KEYNOTE-407 研究的 5 年更新结果。
J Clin Oncol. 2023 Apr 10;41(11):1999-2006. doi: 10.1200/JCO.22.01990. Epub 2023 Feb 3.
2
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.吸烟史与帕博利珠单抗一线治疗晚期非小细胞肺癌患者总生存期的关系。
JAMA Netw Open. 2022 May 2;5(5):e2214046. doi: 10.1001/jamanetworkopen.2022.14046.
3
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.非小细胞肺癌患者一线纳武利尤单抗联合伊匹单抗加两个周期化疗（CheckMate 9LA）：一项国际、随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18.
4
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).免疫检查点抑制剂（ICI）治疗非小细胞肺癌（NSCLC）的临床相关预后和预测标志物。
BMC Cancer. 2020 Dec 3;20(1):1185. doi: 10.1186/s12885-020-07690-8.
5
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.帕博利珠单抗联合化疗对比单纯化疗用于无肿瘤 PD-L1 表达的晚期非小细胞肺癌患者：3 项随机对照研究的汇总分析。
Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11.
6
The Effect of Advances in Lung-Cancer Treatment on Population Mortality.肺癌治疗进展对人群死亡率的影响。
N Engl J Med. 2020 Aug 13;383(7):640-649. doi: 10.1056/NEJMoa1916623.
7
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.帕博利珠单抗联合化疗治疗转移性鳞状非小细胞肺癌患者的随机、安慰剂对照试验：KEYNOTE-407 的方案规定的最终分析。
J Thorac Oncol. 2020 Oct;15(10):1657-1669. doi: 10.1016/j.jtho.2020.06.015. Epub 2020 Jun 26.
8
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.一线帕博利珠单抗治疗 PD-L1 表达非常高的非小细胞肺癌患者的结局。
Ann Oncol. 2019 Oct 1;30(10):1653-1659. doi: 10.1093/annonc/mdz288.
9
Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.帕博利珠单抗作为一线治疗药物治疗程序性死亡配体-1 超高表达的非小细胞肺癌患者的临床结局：日本多中心回顾性队列研究。
PLoS One. 2019 Jul 31;14(7):e0220570. doi: 10.1371/journal.pone.0220570. eCollection 2019.
10
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.